British American Tobacco: FDA Enforcement Shift and Velo's U.S. Surge Rewrite the New Category Playbook
H1 2026 Pre-Close Trading Call, June 2, 2026 — BAT raises Vapour outlook to double-digit growth for the first time in two years as Modern Oral momentum accelerates
The FDA Moment BAT Has Been Waiting For
The single most consequential development in British American Tobacco's H1 2026 update is not a revenue line — it is a regulatory one. The FDA's recently published prioritization guidance, which effectively signals federal intent to enforce against illicit products while carving out a clear pathway for those in scientific review, represents a structural inflection point for the U.S. nicotine market. BAT Chief Executive Tadeu Marroco was unambiguous: "A clear and consistent pathway for scientifically substantiated less risky products to reach the market will support continued progress towards Smokeless America."
For years, BAT has argued that the U.S. vapour market — roughly 93% of which, by the company's own estimate, is dominated by illicit product — has been the primary structural headwind to the Vuse franchise. The FDA's new posture changes the enforcement calculus materially. Marroco put a number on the prize: approximately GBP 7 billion in value currently sitting in the hands of non-compliant players. With around 50% of the U.S. vapour market now located in states that have passed some form of directory and enforcement legislation — up from just 8% in January 2025 — and federal enforcement now layering on top, the trajectory is becoming investable rather than merely aspirational.
U.S. Vapour: From Flat to Double-Digit Growth
The most tangible financial consequence of the improving enforcement environment is a sharp upgrade to U.S. vapour revenue expectations. At the full-year 2025 results, BAT guided for flattish U.S. vapour performance in 2026. The company now expects double-digit U.S. vapour revenue growth for both H1 and the full year — a revision that management attributed primarily to underlying market recovery driven by state-level enforcement, with new product launches providing incremental upside rather than the primary driver. Vuse has gained 4.2 percentage points of U.S. value share year-to-date to reach 56%, and is already delivering positive volume and revenue growth in H1.
The product catalyst that accompanies this is the planned launch of age-gated flavoured Vuse products in Q3. Marroco confirmed that BAT has flavoured vapour products currently in scientific review with the FDA, and that the company is "targeting high compliance retail environments and maintaining a clear, audit-focused position in order to activate flavour vapour commercialisation." The supplemental PMTA pathway, which allows portfolio expansion more efficiently than full PMTAs, adds another tool to that rollout strategy. At the group level, U.S. vapour strength is expected to drive mid-single-digit vapour revenue growth — the first positive full-year outcome in two years.
Velo Plus: The Fastest-Growing Brand in the Fastest-Growing Category
Velo Plus has become BAT's clearest strategic asset in the United States. Year-to-date, the brand has gained 10.4 percentage points of total U.S. Modern Oral volume share to reach 28.4%, and 9.9 percentage points of value share to reach 23.1%. It has achieved category share leadership in seven states and is, according to Marroco, "capturing 100% of category value growth year-to-date." The 70% repurchase rate since the end-of-2024 launch is the metric that most clearly signals genuine consumer adoption rather than trial-driven share inflation.
Velo Max, BAT's next Modern Oral innovation, is scheduled to reach market between August and September. Management was explicit that its margin dynamics will mirror Velo Plus on a per-pouch basis — accretive rather than dilutive to category contribution. The launch is designed to be complementary to the existing portfolio rather than cannibalistic, extending the range upward and capitalising on the FDA's PMTA pilot program, through which BAT sees "a clear pathway to marketing authorisations for our leading higher moisture products."
The broader market opportunity in U.S. Modern Oral remains structurally under-penetrated. Average daily consumption in the U.S. currently stands at 3.6 pouches — versus 6 to 8 in Europe and 12 in Sweden. Marroco argued that given the U.S. has an existing oral tradition, convergence toward Swedish-level consumption is not implausible over time, describing a likely endpoint "somewhere between what Europe is today and Sweden is today." The company expects the global Modern Oral category to nearly triple in revenue by 2030, with Velo outpacing that growth.
New Categories Inflect to Mid-Teens; Profitability Improving
At the group level, BAT now expects New Category revenue growth to accelerate to mid-teens in H1 and for the full year — a meaningful step up from prior expectations. The acceleration is broad-based: Modern Oral delivering strong double-digit growth across all three regions, Vapour returning to growth in the U.S., and further improvement in category-level contribution margins. Globally, Velo extended its volume share lead in top Modern Oral markets to 38.2%, up 740 basis points year-to-date, running at close to six times the scale of the nearest competitor in AME. The company continues to capture over 60% of AME category growth.
The latest innovation, Velo Shift — featuring a new comfort pouch design, five distinct sensory flavours, and a differentiated can — is trading at a premium to the core Velo range and gaining traction in Sweden and Switzerland, with broader European rollout planned through 2026. That premium positioning is consistent with BAT's stated "quality growth discipline" and reinforces the margin improvement trajectory in Modern Oral.
Heated Products: A Structural Reset, Not a Recovery Story
Heated products remain the weakest segment in the portfolio. BAT now guides for low double-digit revenue decline in both H1 and the full year, a material deterioration from the low to mid-single-digit decline previously implied. The primary driver is a significant inventory destocking at the main Japanese distributor — a one-off in nature but one that will drag throughout the year without a second-half rebound. Volume share in top markets declined 1.6 percentage points, with APMEA down 2.1 percentage points and EMEA down 70 basis points. Competitive intensity in the value segment, where BAT was previously dominant with the glo Hyper Pro, has been compounding the pressure.
The strategic response is a two-pronged portfolio reset: glo Hilo targeting the premium segment (over 70% of industry value) in priority markets, and glo Hyper Pro Plus refreshing the value segment with improved consumer experience features including quick-start, longer sessions, and connectivity. Share improvement is expected in H2 as these platforms scale, but Marroco was candid that "there is more work to do." The segment will not be a group earnings driver in 2026.
U.S. Combustibles: Stabilised, Not Deteriorating
U.S. combustibles volume declined approximately 80 basis points in share terms, with value share down 20 basis points, driven by the surge in the deep discount segment and heightened competitive activity in Q4 2025. Critically, management reports that share has been stable since January following targeted promotional investment and a disciplined geographic expansion of the Doral brand into deep-discount-active states. The pace of industry volume decline has moderated to approximately 5% year-to-date on a sales-to-retail basis. BAT expects H1 to be stronger than H2 due to prior-year comparator effects, but sees no further share deterioration as the base case. The Doral rollout — currently live in six additional states beyond the original two pilots — is expected to continue expanding into H2 on a value-accretive basis, with economics dictating the pace rather than any fixed timetable.
APMEA: Bangladesh Drag Compresses Global Volume Outlook
BAT trimmed its global combustible industry volume decline forecast to 2% to 2.5%, from the prior 2%, almost entirely on Bangladesh. A major excise hike implemented last year has created significant market softness, and the upcoming budget season introduces further uncertainty. APMEA progress overall is described as "slower than previously anticipated" in H1. The offsetting dynamic is that H2 2025 was already severely impacted by Australia-related headwinds, meaning comparators become meaningfully easier in the back half of 2026. Management expects APMEA to stabilise through the year and cease being a drag on group performance by 2027.
Deleveraging on Track; GBP 50 Billion FCF Target Intact
BAT continues to target net debt to adjusted EBITDA of 2.0 to 2.5 times by year-end, with operating cash conversion expected to exceed 95% again in 2026. The company reaffirmed its target of delivering more than GBP 50 billion in cumulative free cash flow by end-2030. The GBP 1.3 billion share buyback program is ongoing, and the progressive dividend — now in its 27th consecutive year of growth — remains intact. The Fit2Win restructuring program remains on track for GBP 500 million in annualised savings by end-2027 and GBP 600 million by 2028, with savings realisation weighted to H2 2026. The first-half/second-half profit weighting at the group level reflects both this dynamic and the expected APMEA stabilisation trajectory.
The Honest Caveats
The Middle East remains a genuine watch item. While BAT has seen no material impact on consumer behaviour or supply chain costs to date — noting that roughly two-thirds of its cost base is labor and leaf, insulating it from near-term freight and energy inflation — management was careful not to dismiss the risk. Historical correlation between U.S. gas prices and cigarette consumption is a documented headwind, and if consumer sentiment weakens materially in the back half, the combustibles resilience story faces a genuine test. The Capital Markets Day scheduled for late September at BAT's U.S. headquarters in Winston-Salem will be the next major opportunity to quantify what the FDA enforcement regime means in dollar terms for the medium-term U.S. earnings algorithm — a number investors will want to see before fully repricing the equity.